Abstract
Otelixizumab is a monoclonal antibody (mAb) directed to human CD3ε, a protein forming part of the CD3/T-cell receptor (TCR) complex on T lymphocytes. This study investigated the temporal interaction between varying concentrations of otelixizumab, binding to human CD3 antigen, and expression of CD3/TCR complexes on lymphocytes in vitro, free from the confounding influence of changing lymphocyte frequencies observed in vivo. A static in vitro culture system was established in which primary human peripheral blood mononuclear cells (PBMCs) were incubated over an extended time course with titrated concentrations of otelixizumab. At each time point, free, bound, and total CD3/TCR expression on both CD4+ and CD8+ T cells and the amount of free otelixizumab antibody in the supernatant were measured. The pharmacokinetics of free otelixizumab in the culture supernatants was saturable, with a shorter apparent half-life at low concentration. Correspondingly, a rapid, otelixizumab concentration-, and time-dependent reduction in CD3/TCR expression was observed. These combined observations were consistent with the phenomenon known as target-mediated drug disposition (TMDD). A mechanistic, mathematical pharmacokinetic/pharmacodynamic (PK/PD) m...Continue Reading
References
Nov 1, 1991·European Journal of Immunology·E G RoutledgeH Waldmann
Jul 1, 1991·Neurology·B G WeinshenkerG P Rice
Nov 1, 1982·European Journal of Immunology·L ChatenoudJ F Bach
Oct 1, 1982·Cell·E L ReinherzS F Schlossman
Sep 1, 1994·Clinical Pharmacology and Therapeutics·G Levy
Feb 1, 1993·European Journal of Immunology·S BoltH Waldmann
Apr 21, 1997·The Journal of Experimental Medicine·J A SmithJ A Bluestone
Nov 5, 1999·Science·J F HuangZ Cai
Dec 15, 2000·Immunity·H LiuD A Vignali
Feb 22, 2002·European Journal of Immunology·Charlotte MennéCarsten Geisler
May 10, 2002·Journal of Pharmacokinetics and Pharmacodynamics·D E Mager, W J Jusko
May 31, 2002·The New England Journal of Medicine·Kevan C HeroldJeffrey A Bluestone
Jun 24, 2004·Computer Methods and Programs in Biomedicine·Lars LindbomE Niclas Jonsson
Nov 2, 2004·The Journal of Biological Chemistry·Alicia MonjasBalbino Alarcón
Jun 24, 2005·The New England Journal of Medicine·Bart KeymeulenLucienne Chatenoud
Nov 28, 2006·European Journal of Immunology·Adriana CaballeroJames R Drake
Mar 31, 2009·Analytical Chemistry·Charles CougnonJanine Mauzeroll
Nov 26, 2009·Journal of Clinical Pharmacology·Pawel WiczlingWilliam J Jusko
Jan 12, 2010·Immunology·Devangi S MehtaMichael Rosenzweig
Jul 30, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Leonid Gibiansky, Ekaterina Gibiansky
Sep 18, 2010·Inflammatory Bowel Diseases·C Janneke van der WoudeUNKNOWN Initiative on Crohn's and Colitis, The Netherlands
Oct 16, 2010·Gut·William J SandbornStephan R Targan
Feb 4, 2011·Science Translational Medicine·Chantal KuhnLucienne Chatenoud
Dec 2, 2011·Pharmaceutical Research·Peiming Ma
Jan 27, 2012·Science Translational Medicine·Frank Waldron-LynchKevan C Herold
Jun 27, 2013·Diabetes·William HagopianUNKNOWN Protégé Trial Investigators
Sep 12, 2014·Pharmaceutical Research·Inna VainshteinMeina Liang
Citations
Apr 21, 2016·MAbs·Bram G SengersArmin Sepp
Dec 6, 2017·The AAPS Journal·Anna H C VlotElizabeth C M de Lange
Dec 20, 2018·British Journal of Clinical Pharmacology·Georgios VlasakakisAndre van Maurik
Feb 10, 2021·Journal of Pharmacokinetics and Pharmacodynamics·Begum AlaybeyogluAndrew M Stein